key: cord-0687902-4fh8igym
authors: Al‐Ani, Aysha H.; Johnson, Doug; Christensen, Britt
title: Letter: is pneumococcal vaccination safe during the COVID‐19 pandemic? Authors’ reply
date: 2020-08-14
journal: Aliment Pharmacol Ther
DOI: 10.1111/apt.15940
sha: ccd055482cc430a6ceded5c2bd52799bce3e5159
doc_id: 687902
cord_uid: 4fh8igym

LINKED CONTENT This article is linked to Al‐Ani et al and Deniz et al papers. To view these articles, visit https://doi.org/10.1111/apt.15779 and https://doi.org/10.1111/apt.15903

We acknowledge the concern outlined by Deniz et al in regard to the possible detrimental effect of pneumococcal vaccination on a patient with probable or co-existing COVID-19 due to the potential for progression to cytokine storm, acute respiratory distress syndrome and death as a result of NLRP3 inflammasome activation and consequent hyperinflammatory response. 1 Triggering the NLRP3 inflammasome by intracellular viral pathogens may lead to excessive production of IL-1β with potentially pathological consequences. 1 However, we wish to reiterate that our recommendations regarding pneumococcal vaccination for patients with IBD centre around optimising as many modifiable factors in patients who are likely to be, or due to be, immunocompromised. 2 This is especially important given that bacterial co-infection, including

Streptococcus pneumoniae, has been described in up to 50% of patients with COVID-19 and has been associated with significantly reduced survival. 3, 4 Patients with IBD are at increased risk of vaccine-preventable diseases. 5 Current recommendations for patients with chronic inflammatory diseases maintained on immunosuppressive medications state that inactivated vaccines should be administered to this population. 6 In regard to pneumococcal vaccine, PCV13 (pneumococcal polysaccharide conjugated) should be administered to patients with chronic inflammatory conditions being treated with immunosuppression. 6 PPSV23 (pneumococcal purified capsular polysaccharides) should be administered to patients with planned commencement of low-or high-level immunosuppression. 6 It is the shared responsibility of the specialist and primary care provider to ensure that appropriate vaccinations are administered to immunocompromised patients as per current guidelines. 6 

The authors' declaration of personal and funding interests are unchanged from those in the original article. 2 

Letter: is pneumococcal vaccination safe during COVID-19 pandemic

Review article: prevention, diagnosis and management of COVID-19 in the IBD patient

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Co-infections among patients with COVID-19: The need for combination therapy with nonanti-SARS-CoV-2 agents?

Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

IDSA clinical practice guideline for vaccination of the immunocompromised host

β-Confident-registry: aiming to be largest-ever studied cohort of cryopyrin-associated periodic syndromes (CAPS) patients. Study design and baseline characteristics

Brief report: severe inflammation following vaccination against Streptococcus pneumoniae in patients with cryopyrin-associated periodic syndromes

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations

The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: a systematic review and meta-analysis. Vaccine